EMA mulls appeal after EU court rules against trial data disclosure
This article was originally published in SRA
Executive Summary
The European Medicines Agency says it may appeal against interim rulings by the EU General Court ordering it to refrain from publishing clinical trial data on AbbVie's Humira (adalimumab) and Intermune's Esbriet (pirfenidone) pending a final decision from the court1.